Lite Strategy, Inc. Operating Lease Cost
Lite Strategy, Inc. (LITS) reported Operating Lease Cost of $0 for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2025-11-14
- Lite Strategy, Inc. operating lease, cost for the quarter ending 2025-09-30 was $0.00.
- Lite Strategy, Inc. operating lease, cost for the quarter ending 2023-03-31 was $609.00K, a 61.54% increase year-over-year.
- Lite Strategy, Inc. operating lease, cost for the quarter ending 2022-12-31 was $608.00K, a 61.27% increase year-over-year.
- Lite Strategy, Inc. operating lease, cost for the quarter ending 2022-06-30 was $453.00K, a 20.16% increase year-over-year.
- Lite Strategy, Inc. operating lease, cost for fiscal 2022 was $1.58M, a 5.04% increase from fiscal 2021.
- Lite Strategy, Inc. operating lease, cost for fiscal 2021 was $1.51M, a 117.77% increase from fiscal 2020.
- Lite Strategy, Inc. operating lease, cost for fiscal 2020 was $692.00K, a 1.02% increase from fiscal 2019.
- Lite Strategy, Inc. operating lease, cost for fiscal 2019 was $685.00K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-14 | |||
| 2023-03-31 | $609.00K 10-Q · filed 2023-05-11 | $1.22M derived: sum of 2 quarters · filed 2023-05-11 | $1.83M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $608.00K 10-Q · filed 2023-02-09 | $1.22M 10-Q · filed 2023-02-09 | ||
| 2022-06-30 | $453.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-08 | $830.00K derived: sum of 2 quarters · filed 2023-05-11 | $1.21M derived: sum of 3 quarters · filed 2023-05-11 | $1.58M 10-K · filed 2022-09-08 |
| 2022-03-31 | $377.00K 10-Q · filed 2023-05-11 | $754.00K derived: sum of 2 quarters · filed 2023-05-11 | $1.13M 10-Q · filed 2023-05-11 | $1.51M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $377.00K 10-Q · filed 2023-02-09 | $753.00K 10-Q · filed 2023-02-09 | $1.13M derived: sum of 3 quarters · filed 2023-02-09 | $1.51M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-09-30 | $377.00K 10-Q/A · filed 2022-05-23 | $754.00K derived: sum of 2 quarters · filed 2022-09-08 | $1.13M derived: sum of 3 quarters · filed 2022-09-08 | $1.51M derived: sum of 4 quarters · filed 2022-09-08 |
| 2021-06-30 | $377.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-08 | $754.00K derived: sum of 2 quarters · filed 2022-09-08 | $1.13M derived: sum of 3 quarters · filed 2022-09-08 | $1.51M 10-K · filed 2022-09-08 |
| 2021-03-31 | $377.00K 10-Q · filed 2022-05-23 | $754.00K derived: sum of 2 quarters · filed 2022-05-23 | $1.13M 10-Q · filed 2022-05-23 | $1.22M derived: sum of 4 quarters · filed 2022-09-08 |
| 2020-12-31 | $377.00K 10-Q/A · filed 2022-05-23 | $753.00K 10-Q/A · filed 2022-05-23 | $843.00K derived: sum of 3 quarters · filed 2022-09-08 | $1.04M derived: sum of 4 quarters · filed 2022-09-08 |
| 2020-09-30 | $377.00K 10-Q/A · filed 2022-05-23 | $466.00K derived: sum of 2 quarters · filed 2022-09-08 | $667.00K derived: sum of 3 quarters · filed 2022-09-08 | $881.00K derived: sum of 4 quarters · filed 2022-09-08 |
| 2020-06-30 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-08 | $290.00K derived: sum of 2 quarters · filed 2022-09-08 | $504.00K derived: sum of 3 quarters · filed 2022-09-08 | $692.00K 10-K · filed 2022-09-08 |
| 2020-03-31 | $201.00K 10-Q · filed 2021-05-06 | $415.00K derived: sum of 2 quarters · filed 2021-05-06 | $603.00K 10-Q · filed 2021-05-06 | |
| 2019-12-31 | $214.00K 10-Q · filed 2021-02-04 | $402.00K 10-Q · filed 2021-02-04 | ||
| 2019-06-30 | $685.00K 10-K/A · filed 2022-05-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |